Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection

Bile acids exist in different forms that can either favour or block the regrowth of C. difficile after treatment.